Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action.
Ontology highlight
ABSTRACT: Inclusion of pregnant women in COVID-19 clinical trials would allow evaluation of effective therapies that might improve maternal health, pregnancy, and birth outcomes, and avoid the delay of developing treatment recommendations for pregnant women. We explored the inclusion of pregnant women in treatment trials of COVID-19 by reviewing ten international clinical trial registries at two timepoints in 2020. We identified 155 COVID-19 treatment studies of non-biological drugs for the April 7-10, 2020 timepoint, of which 124 (80%) specifically excluded pregnant women. The same registry search for the July 10-15, 2020 timepoint, yielded 722 treatment studies, of which 538 (75%) specifically excluded pregnant women. We then focused on studies that included at least one of six drugs (remdesivir,
SUBMITTER: Taylor MM
PROVIDER: S-EPMC7832459 | biostudies-literature | 2021 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA